

Key Indices Update

Indices	Close	Change (%)
Nifty	24708.40	0.98 7
Sensex	81765.86	1.00 7
Midcap	58441.55	0.57 7
Smallcap	19333.55	0.83 7

Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
26	1483 /1304

Key Data

Data	Current	Previous
Dow Jones	44,724.1	44,793.1
U.S. Dollar Index	105.84	106.37
Brent Crude (USD/BBL)	71.78	73.64
US 10Y Bond Yield (%)	4.18	4.23
India 10Y Bond Yield (%)	6.73	6.84

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	53,603.55	0.63 7
NIFTYAUTO	23,736.25	0.65 7
NIFTYENERGY	37,884.70	0.39 7
NIFTYFINSRV	26,474.55	0.54 7
NIFTYFMCG	57,605.20	0.58 7
NIFTYIT	44,806.40	1.95 7
NIFTYMEDIA	2,083.95	0.01 7
NIFTYMETAL	9,282.75	0.57 7
NIFTYPHARMA	22,463.40	0.18 7
NIFTYREALTY	1,074.45	ע 0.25

Flls F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	2411.78	5.37%
Index Options	78837.08	-33.43%
Stock Futures	6825.28	2.43%
Stock Options	-825.23	13.62%

Fll & Dll Cash Segment (₹ in cr)

Category	Amount	MTD	YTD
FII	8539.91	10338.00	-235410
DII	-2303.64	133.00	177173

				DECEMBER 06, 2024
Fundamente	al			Refer Page 02
Stock for Inves	tment			
Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
RATEGAIN	IT	725	868	19.8%
			*CN	IP as on Dec. 05, 2024

Top News

- Kolte-Patil Developers Ltd. is selling a 17% equity stake in Kolte-Patil Planet Kiwale Project Pvt. Ltd. to Kolte-Patil Planet Real Estate Pvt. Ltd. for Rs. 3.79 crores.
- KIMS has acquired an additional 3.00% equity stake in its subsidiary, Arunodaya Hospitals, raising its total holding to 70.66%.




- NIFTY experienced a volatile session and recovered approximately 400 points from day lows and closed with a percent gain.
- + Almost all the sectors ended positive, with **IT and Auto being the major contributors** while Realty witnessed mild profit taking.
- + Traders are advised to stay with **bullish tone which can inch** index higher with 24500 as major support.
- + Stock of the day HINDPETRO.



Market Radiance

Fundamental

Top **News**







Technical

Edged higher after a day of pause. Stay selective.

NIFTY	S1	S2	RÌ	R2
24708.40 7 240.95 (0.98%)	24540	24350	24900	25100



- NIFTY experienced a volatile session and recovered approximately 400 points from day lows.
- + A breakout above the inverted head and shoulder pattern is witnessed.
- + Almost all the sectors ended positive, with **IT and Auto being the major contributors.**
- Traders are advised to focus on a stock-specific approach and can consider a bullish tone to continue with 24350 as major support.

BANKNIFTY	S1	S2	RI	R2
53603.55 🛪 336.65 (0.63%)	53200	52800	54000	54500



- Bank Nifty has gained for 5 consecutive days with strong bullish follow-on in continuation to the prevailing trend.
- + The index during the first half witnessed profit-taking, followed with a swift **rebound recovering nearly 1000 points from lows.**
- + Also, HDFCBANK has registered a fresh all-time high, contributing to additional gains.
- + Stay cautious at volatility in index **keeping bullish trend** as primary.
- + Traders are recommended to stay with buying on dips.



Market Radiance

a

Technical

Stock of the day	Recom.	СМР (₹)	Range*	SL	Target
HINDPETRO	BUY	392.6	390-393	383	412



	Name	Price	Price %
	TRIVENI	441.80	8.13 7
ap	BALAJITELE_T	73.13	6.62 7
Midcap	KPIL	1237.80	6.14 7
-	FINCABLES	1299.95	6.08 7
	CASTROLIND	218.84	5.44 7

10
S
Φ
2
.=
0
Q
0
Š
ĩ
_
വ
~
0
0

Momentum Stocks

Name	Price	Price %
BSE	5227.70	14.34 7
CDSL	1857.05	8.06 7
IGL	383.20	6.37 7
ANGELONE	3224.00	6.33 7
GRANULES	568.30	4.65 7

Name	Price	Price %	Тор
IDEA	8.07	ע 4.16	т б л
OIL	474.20	ע 3.05	F&O
SHREECEM	26599.00	ע 2.94	
DIVISLAB	6099.70	ע 2.51	Losers
ADANIGREEN	1229.50	ע 2.49	Ľ

Name	Price	Price %	_
SONACOMS	675.25	لا 2.02	Bearish
DELHIVERY	333.30	لا 2.00	
SBILIFE	1435.00	וע 1.21	Charts
AUROPHARMA	1245.50	וע 1.10	rts
HDFCLIFE	643.15	ע 1.09	

+	HINDPETRO	has	advanced	towards
	breakout fro	om its	consolidatio	n range.

- + Stock has faced a correction phase previously and settled near its 100 DEMA.
- + Stock consolidated above its 100 DEMA, simultaneously beholding a **breakout from** the consolidation zone.
- + **Recommendation:** We maintain momentum buy on the stock.
- + Traders are recommended to accumulate the stock in the mentioned range and 410-415 as the first swing target.

Name	Price	Price %	-
CESC	192.15	2.97 7	Ranç Bi
ΡΑΥΤΜ	959.00	2.04 7	Inge Breakou Breakdown
ICICIBANK	1336.55	1.56 7	reak
AARTIIND	449.80	0.60 7	/n /n
SBIN	864.25	0.53 7	

arts	zo
cho	м
llish	C
Bul	IN

Name	Price	Price %
ZOMATO	299.00	4.45 7
MAXHEALTH	1096.30	3.01 7
CESC	192.15	2.97 7
INFY	1935.00	2.42 7
CHAMBLFERT	546.05	2.19 7



Market Radiance Click : Read : Repeat

Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Aniket Varshney	aniket.varshney@religare.com



Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Market Radiance

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results